{"product_id":"prqr-ansoff-analysis","title":"(PRQR) ProQR Therapeutics N.V. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis ProQR Therapeutics N.V. Ansoff Matrix Analysis maps the company’s growth choices across market penetration, market development, product development, and diversification to guide strategy, investment, or planning decisions. The page contains a genuine preview\/sample of the actual analysis so you can evaluate style and substance before buying; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSepofarsen Phase II\/III ILLUMINATE in LCA10\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSepofarsen in ProQR Therapeutics N.V.’s Phase II\/III ILLUMINATE trial is a market penetration play because it targets the same inherited retinal disease niche, Leber Congenital Amaurosis 10, rather than a new market. LCA10 is a rare, genetically defined disorder, so the patient pool is already known and relatively small, which supports focused adoption if efficacy and safety stay strong. This deepens ProQR Therapeutics N.V.’s position in a familiar indication and can lift share without changing the core market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltevursen Phase II\/III in USH2A Retinal Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltevursen in Phase II\/III keeps ProQR Therapeutics N.V. focused on USH2A-linked retinitis pigmentosa and Usher syndrome, two rare inherited retinal diseases affecting about 1 in 4,000 and 1 in 6,000 to 1 in 10,000 people, respectively. This is classic market penetration: advancing one existing candidate deeper in the same ophthalmology niche, not chasing a new disease area. It strengthens ProQR’s foothold in inherited retinal disorders and preserves domain focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInherited Retinal Disorder Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProQR’s core pipeline is concentrated in inherited retinal disorders, a niche that affects about 1 in 3,000 to 1 in 4,000 people and is served by few direct rivals. That focus makes market penetration easier than in broad disease areas, because each new study, site, and patient can build share in the same specialized field.\u003c\/p\u003e\n\u003cp\u003eWith no broad commercial spread across unrelated therapies, ProQR’s clearest near-term penetration target is the retinal gene-therapy segment, where its eye-only R\u0026amp;D spend is aligned with one narrow market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRNA Therapeutics in Rare Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQR Therapeutics N.V. stays tightly focused on RNA therapeutics for rare genetic diseases, which strengthens market penetration by keeping its message, platform, and pipeline aimed at the same specialist audience. With over 300 million people living with rare diseases worldwide and more than 7,000 known rare disorders, that focus helps ProQR build clearer recognition among clinicians and researchers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRNA-first identity supports specialist trust\u003c\/li\u003e\n\u003cli\u003eShared science lowers marketing drift\u003c\/li\u003e\n\u003cli\u003eNarrow focus improves pipeline clarity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic and Clinical Collaboration Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQR Therapeutics N.V. uses its academic and clinical collaboration network as a market penetration lever in its current RNA-based therapy space. The company has licensing agreements with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, and Leiden University Medical Center, giving it four named external links that support translational work, scientific access, and execution without shifting its core focus.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFour licensing relationships support current market reach.\u003c\/li\u003e\n\u003cli\u003eAcademic partners add translational and clinical expertise.\u003c\/li\u003e\n\u003cli\u003eHelps deepen execution without changing product focus.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProQR’s Growth Play: Win Bigger in Rare Eye Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V.’s market penetration is centered on deepening share in inherited retinal disease, not expanding into new markets. Sepofarsen and ultevursen both target known rare-eye niches, where ProQR can build clinician trust and patient reach in the same specialist base. This fits a narrow, high-friction market with few direct rivals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease base\u003c\/td\u003e\n\u003ctd\u003e7,000+ disorders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIRD prevalence\u003c\/td\u003e\n\u003ctd\u003e1 in 3,000 to 4,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSH2A RP\u003c\/td\u003e\n\u003ctd\u003e1 in 4,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes ProQR Therapeutics N.V.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise ProQR Therapeutics N.V. Ansoff Matrix analysis to quickly clarify growth options and ease strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, regulatory, and peer-reviewed sources to validate ProQR growth paths, enabling rapid verification and defensible Ansoff Matrix decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGaining Access Through Eli Lilly Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V.’s partnership with Eli Lilly and Company opens access to two new disease areas: genetic conditions of the liver and nervous system.\u003c\/p\u003e\n\u003cp\u003eThe deal uses ProQR’s RNA expertise to move beyond its retinal disease focus and into broader rare-disease markets.\u003c\/p\u003e\n\u003cp\u003eThat shift matters because one platform can now support multiple therapeutic fields, widening ProQR’s commercial reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntering Systemic Genetic Disease Areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Lilly agreement moves ProQR Therapeutics N.V. from 1 core eye-disease field into 2 new systemic areas: liver and nervous system disease. That is classic market development, because the company is entering new markets with existing RNA-editing know-how rather than only growing in ophthalmology. Partnering, not in-house commercialization, is the faster way to reach these segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeveraging Axiomer Beyond Eye Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V.’s Axiomer RNA base-editing platform can be reused beyond inherited retinal disease, so it fits market development: one core technology, new therapeutic markets. The company has already moved Axiomer into additional disease areas, widening its addressable patient base beyond eye disorders. That gives ProQR a second growth path without rebuilding the platform from scratch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-Institution Collaboration Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQR Therapeutics N.V. is widening its market reach through 4 key partnerships with Radboud, Inserm, Ionis, and LUMC. This gives the Company access to Dutch, French, and US-linked research ecosystems, which raises the odds of new R\u0026amp;D programs and broader licensing reach. In Ansoff terms, this is market development through external network expansion, not just internal pipeline growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 institutional partnerships\u003c\/li\u003e\n\u003cli\u003eBroader scientific reach\u003c\/li\u003e\n\u003cli\u003eMore future program options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEuropean and International Research Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQR Therapeutics N.V., headquartered in Leiden, can expand beyond the Netherlands through its European and international research network, which supports market development without a stand-alone sales push. By working with non-company institutions, it can reach more patient groups and scientists across new geographies while keeping development risk shared. That fits Ansoff market development: same science, wider markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eLeiden base supports cross-border research access.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eInstitutional partners widen patient and scientist reach.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eCollaborative entry lowers market-expansion risk.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProQR’s Axiomer Expands Into Liver and Nervous System Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V.’s market development is clear: its Eli Lilly and Company deal extends Axiomer beyond eye disease into 2 new areas, liver and nervous system disorders. That broadens reach without rebuilding the platform, and 4 partnerships with Radboud, Inserm, Ionis, and LUMC further expand cross-border access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew markets\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey partnerships\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore platform\u003c\/td\u003e\n\u003ctd\u003eAxiomer RNA editing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eProQR Therapeutics N.V. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report and reflects the complete strategic evaluation for ProQR Therapeutics N.V., including growth options, risks, and actionable recommendations. Unlock the editable, full-version after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSepofarsen Clinical Advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSepofarsen is in Phase II\/III testing, so ProQR Therapeutics N.V. is still refining the RNA therapy rather than building a new market. In LCA10, this is classic product development: improve one candidate inside its core ophthalmology area. The goal is to move a new treatment closer to possible use in a known rare-disease segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltevursen Clinical Advancement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltevursen is in Phase II\/III, so ProQR Therapeutics N.V. is adding another late-stage asset to its retinal disease pipeline. It is a clear product development move: a new therapy aimed at the same rare-eye-disease market, with inherited retinal disorders still the core focus. This broadens the company’s product set and lowers reliance on a single program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAxiomer Platform Maturation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V. is maturing its Axiomer RNA base-editing platform, and that matters because one technology base can feed multiple new drug candidates. In its FY2025 reporting, the company kept Axiomer at the center of product creation in genetic disease, which supports the Product Development move in Ansoff Matrix terms. As the platform expands, ProQR can widen its pipeline without rebuilding core science from scratch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRNA-Based Novel Medicines Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQR Therapeutics N.V. keeps product development inside one RNA engine, so new medicines come from the same discovery platform. In FY2025, that meant expanding its RNA-based pipeline in the same rare-disease markets, which fits Ansoff’s product development move: new products, same customers and science.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame RNA biology platform\u003c\/li\u003e\n\u003cli\u003eNew candidates for rare diseases\u003c\/li\u003e\n\u003cli\u003eFits existing market expansion\u003c\/li\u003e\n\u003cli\u003eHigh R\u0026amp;D, no commercial product\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensed Innovation Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQR Therapeutics N.V. uses licensing deals with Radboud, Inserm, Ionis, and LUMC to pull in proprietary science that can seed new RNA therapy candidates over time. This fits Ansoff’s product development path: add products from outside inputs while staying in the same core field. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew candidates come from licensed science\u003c\/li\u003e\n\u003cli\u003eCore focus stays on RNA therapeutics\u003c\/li\u003e\n\u003cli\u003ePartners widen the pipeline without a pivot\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProQR’s RNA Pipeline Advances on Two Fronts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V.’s Product Development is clear: it keeps building new RNA therapies from the same rare-eye-disease base. Sepofarsen and Ultevursen were both in Phase II\/III in FY2025, while Axiomer stayed the platform for new genetic-disease candidates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFY2025 driver\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSepofarsen\u003c\/td\u003e\n\u003ctd\u003ePhase II\/III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUltevursen\u003c\/td\u003e\n\u003ctd\u003ePhase II\/III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore engine\u003c\/td\u003e\n\u003ctd\u003eAxiomer platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEli Lilly Collaboration in Liver and Nervous System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V.’s Eli Lilly collaboration is its clearest diversification move: it takes ProQR beyond eye disease into genetic conditions of the liver and nervous system. This adds a new disease scope and a new therapeutic setting, so growth is no longer tied only to retinal programs. In Ansoff terms, it is a true diversification play, creating a separate path for value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAxiomer Into New Therapeutic Domains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V.'s Axiomer base-editing platform is built for more than eye disease, so it can move into other therapeutic areas and new product classes. That matters because a single platform can support multiple targets and lower dependence on ophthalmology, where ProQR has spent years building its RNA-editing expertise. With Axiomer, ProQR is set up to widen its addressable market and diversify beyond its current pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Retinal Disease to Systemic Genetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSepofarsen and Ultevursen target inherited retinal disorders, while ProQR Therapeutics N.V.’s Lilly partnership moves into systemic genetic diseases. That is diversification across disease classes, not just a bigger pipeline. It broadens exposure beyond 2 retinal programs and reduces reliance on one therapeutic segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-Partner Innovation Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQR Therapeutics N.V. uses a multi-partner model to tap external science and move into adjacent RNA areas without funding every step in-house. That fits diversification in the Ansoff Matrix because new ideas can be tested in new markets through licensing and research deals. \u003c\/p\u003e\n\u003cp\u003eFor a small biotech, this lowers capital risk and widens the pipeline faster than solo discovery. It also lets Company Name spread R\u0026amp;D across partners while keeping focus on core ophthalmology and RNA editing expertise. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses outside science to enter new areas.\u003c\/li\u003e\n\u003cli\u003eShares cost and risk with partners.\u003c\/li\u003e\n\u003cli\u003eSupports new products in new markets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRNA Editing Beyond Current Clinical Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQR’s strongest diversification lever is Axiomer, because sepofarsen and ultevursen stay tied to inherited retinal disease, while Axiomer can open new disease programs beyond that narrow base. RNA editing widens the Ansoff path from current late-stage assets into new products for new markets over time. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eSepofarsen and ultevursen are the current late-stage assets.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAxiomer expands into diseases not covered by both.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eIt is the clearest diversification move in the portfolio.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProQR’s Axiomer Expands Growth Beyond Eye Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProQR Therapeutics N.V.’s clearest diversification move is Axiomer, which can reach genetic diseases beyond inherited retinal disorders. That shifts growth beyond sepofarsen and ultevursen, so the portfolio is not tied to one eye-disease niche. In Ansoff terms, this is true diversification: new products, new disease areas, and a wider market base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAxiomer\u003c\/td\u003e\n\u003ctd\u003eMoves beyond ophthalmology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLilly deal\u003c\/td\u003e\n\u003ctd\u003eOpens new systemic genetic areas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234857328905,"sku":"prqr-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/prqr-ansoff-matrix.webp?v=1785729189","url":"https:\/\/dcfanalyst.com\/products\/prqr-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}